(CTRE) CareTrust REIT - Overview
Stock: Skilled Nursing, Senior Housing, Healthcare Properties, Net-Leased, Real Estate
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 4.16% |
| Yield on Cost 5y | 7.40% |
| Yield CAGR 5y | 6.04% |
| Payout Consistency | 91.8% |
| Payout Ratio | 135.1% |
| Risk 5d forecast | |
|---|---|
| Volatility | 21.6% |
| Relative Tail Risk | 1.33% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.89 |
| Alpha | 45.06 |
| Character TTM | |
|---|---|
| Beta | 0.186 |
| Beta Downside | 0.193 |
| Drawdowns 3y | |
|---|---|
| Max DD | 23.19% |
| CAGR/Max DD | 1.35 |
Description: CTRE CareTrust REIT January 08, 2026
CareTrust REIT (CTRE) is a self-administered, publicly-traded REIT that acquires, develops, and leases skilled-nursing, senior-housing, and other healthcare-related properties across the United States and the United Kingdom. Since its spin-off on June 1 2014, the portfolio has grown to 390 net-leased properties (≈35,687 beds/units) in 31 U.S. states and the U.K., with an additional 23 related investments covering 143 properties (≈14,082 beds/units) and one financing receivable tied to 46 properties (≈3,820 beds/units) as of September 30 2025.
Key sector drivers include the aging-population tailwind-U.S. Census data projects the 65-plus cohort to reach 21 % of the population by 2030-and the relative resilience of healthcare REITs to economic cycles because lease structures are often backed by government programs (e.g., Medicare/Medicaid). Recent quarterly filings show a funds-from-operations (FFO) growth rate of ~7 % YoY, with an occupancy rate of 93 % across the core portfolio, and an average lease term of 12 years, which helps mitigate interest-rate volatility that typically pressures REIT valuations.
For a deeper, data-driven view of CTRE’s valuation metrics and scenario analysis, you may find the free research tools on ValueRay worth a quick look.
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income: 261.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA -0.47 > 1.0 |
| NWC/Revenue: 206.1% < 20% (prev 134.2%; Δ 71.94% < -1%) |
| CFO/TA 0.07 > 3% & CFO 348.3m > Net Income 261.4m |
| Net Debt (181.3m) to EBITDA (381.8m): 0.47 < 3 |
| Current Ratio: 4.76 > 1.5 & < 3 |
| Outstanding Shares: last quarter (212.3m) vs 12m ago 32.79% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 8.09% > 50% (prev 7.52%; Δ 0.58% > 0%) |
| Interest Coverage Ratio: 8.02 > 6 (EBITDA TTM 381.8m / Interest Expense TTM 37.5m) |
Altman Z'' 0.52
| A: 0.13 (Total Current Assets 846.1m - Total Current Liabilities 177.9m) / Total Assets 5.09b |
| B: -0.10 (Retained Earnings -528.3m / Total Assets 5.09b) |
| C: 0.08 (EBIT TTM 300.5m / Avg Total Assets 4.00b) |
| D: -0.49 (Book Value of Equity -522.3m / Total Liabilities 1.07b) |
| Altman-Z'' Score: 0.52 = B |
What is the price of CTRE shares?
Over the past week, the price has changed by +6.67%, over one month by +5.17%, over three months by +6.95% and over the past year by +55.07%.
Is CTRE a buy, sell or hold?
- StrongBuy: 6
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the CTRE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 41.5 | 6.7% |
| Analysts Target Price | 41.5 | 6.7% |
| ValueRay Target Price | 52.3 | 34.5% |
CTRE Fundamental Data Overview February 09, 2026
P/E Forward = 12.9702
P/S = 20.2414
P/B = 2.1714
P/EG = 1.26
Revenue TTM = 324.1m USD
EBIT TTM = 300.5m USD
EBITDA TTM = 381.8m USD
Long Term Debt = 893.8m USD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 893.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 181.3m USD (from netDebt column, last quarter)
Enterprise Value = 8.85b USD (8.67b + Debt 893.8m - CCE 712.5m)
Interest Coverage Ratio = 8.02 (Ebit TTM 300.5m / Interest Expense TTM 37.5m)
EV/FCF = 26.48x (Enterprise Value 8.85b / FCF TTM 334.4m)
FCF Yield = 3.78% (FCF TTM 334.4m / Enterprise Value 8.85b)
FCF Margin = 103.2% (FCF TTM 334.4m / Revenue TTM 324.1m)
Net Margin = 80.64% (Net Income TTM 261.4m / Revenue TTM 324.1m)
Gross Margin = unknown ((Revenue TTM 324.1m - Cost of Revenue TTM 11.1m) / Revenue TTM)
Tobins Q-Ratio = 1.74 (Enterprise Value 8.85b / Total Assets 5.09b)
Interest Expense / Debt = 1.41% (Interest Expense 12.6m / Debt 893.8m)
Taxrate = 2.70% (2.08m / 77.0m)
NOPAT = 292.4m (EBIT 300.5m * (1 - 2.70%))
Current Ratio = 4.76 (Total Current Assets 846.1m / Total Current Liabilities 177.9m)
Debt / Equity = 0.22 (Debt 893.8m / totalStockholderEquity, last quarter 3.99b)
Debt / EBITDA = 0.47 (Net Debt 181.3m / EBITDA 381.8m)
Debt / FCF = 0.54 (Net Debt 181.3m / FCF TTM 334.4m)
Total Stockholder Equity = 3.28b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.53% (Net Income 261.4m / Total Assets 5.09b)
RoE = 7.96% (Net Income TTM 261.4m / Total Stockholder Equity 3.28b)
RoCE = 7.20% (EBIT 300.5m / Capital Employed (Equity 3.28b + L.T.Debt 893.8m))
RoIC = 7.13% (NOPAT 292.4m / Invested Capital 4.10b)
WACC = 6.11% (E(8.67b)/V(9.57b) * Re(6.60%) + D(893.8m)/V(9.57b) * Rd(1.41%) * (1-Tc(0.03)))
Discount Rate = 6.60% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 41.41%
[DCF Debug] Terminal Value 87.68% ; FCFF base≈282.9m ; Y1≈349.0m ; Y5≈594.4m
Fair Price DCF = 71.49 (EV 16.14b - Net Debt 181.3m = Equity 15.96b / Shares 223.3m; r=6.11% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 33.51 | EPS CAGR: -42.12% | SUE: -4.0 | # QB: 0
Revenue Correlation: 86.24 | Revenue CAGR: 22.23% | SUE: -1.11 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.39 | Chg30d=-0.045 | Revisions Net=-1 | Analysts=2
EPS next Year (2026-12-31): EPS=1.67 | Chg30d=-0.093 | Revisions Net=+1 | Growth EPS=-5.7% | Growth Revenue=+23.7%